186 related articles for article (PubMed ID: 18040025)
1. Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Kass DA; Champion HC; Beavo JA
Circ Res; 2007 Nov; 101(11):1084-95. PubMed ID: 18040025
[TBL] [Abstract][Full Text] [Related]
2. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
[TBL] [Abstract][Full Text] [Related]
3. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
4. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 5 inhibitors: are they cardioprotective?
Reffelmann T; Kloner RA
Cardiovasc Res; 2009 Jul; 83(2):204-12. PubMed ID: 19474180
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
Nagendran J; Archer SL; Soliman D; Gurtu V; Moudgil R; Haromy A; St Aubin C; Webster L; Rebeyka IM; Ross DB; Light PE; Dyck JR; Michelakis ED
Circulation; 2007 Jul; 116(3):238-48. PubMed ID: 17606845
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
Francis SH; Corbin JD
Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
Menniti FS; Ren J; Coskran TM; Liu J; Morton D; Sietsma DK; Som A; Stephenson DT; Tate BA; Finklestein SP
J Pharmacol Exp Ther; 2009 Dec; 331(3):842-50. PubMed ID: 19729580
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
10. Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A.
Carøe Nordgaard J; Kruse LS; Gammeltoft S; Kruuse CR
PLoS One; 2014; 9(9):e107627. PubMed ID: 25247292
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase regulation of nitric oxide signaling.
Kass DA; Takimoto E; Nagayama T; Champion HC
Cardiovasc Res; 2007 Jul; 75(2):303-14. PubMed ID: 17467673
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterases and cardiac cGMP: evolving roles and controversies.
Zhang M; Kass DA
Trends Pharmacol Sci; 2011 Jun; 32(6):360-5. PubMed ID: 21477871
[TBL] [Abstract][Full Text] [Related]
13. Real-time monitoring of phosphodiesterase inhibition in intact cells.
Herget S; Lohse MJ; Nikolaev VO
Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
[TBL] [Abstract][Full Text] [Related]
14. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.
Burnett AL
J Androl; 2008; 29(1):3-14. PubMed ID: 17942972
[TBL] [Abstract][Full Text] [Related]
15. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Wong P; Lawrentschuk N; Bolton DM
Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
[TBL] [Abstract][Full Text] [Related]
17. Identification of PDE5A:E90K: a polymorphism in the canine phosphodiesterase 5A gene affecting basal cGMP concentrations of healthy dogs.
Stern JA; Reina-Doreste Y; Chdid L; Meurs KM
J Vet Intern Med; 2014; 28(1):78-83. PubMed ID: 24341639
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity.
Gebska MA; Stevenson BK; Hemnes AR; Bivalacqua TJ; Haile A; Hesketh GG; Murray CI; Zaiman AL; Halushka MK; Krongkaew N; Strong TD; Cooke CA; El-Haddad H; Tuder RM; Berkowitz DE; Champion HC
Cardiovasc Res; 2011 May; 90(2):353-63. PubMed ID: 21421555
[TBL] [Abstract][Full Text] [Related]
19. Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension.
Ueda Y; Johnson LR; Ontiveros ES; Visser LC; Gunther-Harrington CT; Stern JA
Sci Rep; 2019 May; 9(1):6899. PubMed ID: 31053768
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of tissue-selective drug action in the cardiovascular system.
Barrett TD; Triggle DJ; Walker MJ; Maurice DH
Mol Interv; 2005 Apr; 5(2):84-93. PubMed ID: 15821157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
